Summit falls after FDA letter raises concerns on development capabilities
SMMT•Summit Therapeutics shares fell 3% premarket after the FDA outlined concerns about the company’s application for experimental lung cancer drug ivonescimab. Bernstein cut its rating to underperform from market-perform and its price target to $8.30 from $11.90.
1. FDA cites study concerns
The FDA published a letter outlining why it would decline approval for Summit Therapeutics’ ivonescimab application. The agency said the study initially enrolled about 60% of patients in China, with North American and European patients added later, leaving a 17-month gap between the first enrollments in those regions. The FDA said 93% of events showing reduced cancer-progression risk came from China, raising concerns about applicability to U.S. patients.
2. Analyst cuts outlook
Bernstein said four early data cuts increased the risk of a poor regulatory outcome and that Summit could have been more transparent about regional risks. The brokerage lowered its rating to underperform from market-perform, cut its price target to $8.30 from $11.90, and reduced its success odds for all ongoing late-stage ivonescimab studies by 25% over clinical and regulatory execution concerns. Summit shares were down about 39% year to date through the prior close.




